Ossification

Orthofix Announces New President for Bone Growth Therapies Business

Retrieved on: 
Thursday, February 29, 2024
Health, Medical Devices, Hospitals, Surgery, Health Technology, General Health, Biotechnology, Enabling, Marketing, Multimedia, Shallenberger, Spine, University, Patient, Boehringer Ingelheim, Ossification, Pharmaceutical industry

(NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Jason Shallenberger to President of the Bone Growth Therapies business, and the realignment of its Spine business unit, effective March 1.

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Jason Shallenberger to President of the Bone Growth Therapies business, and the realignment of its Spine business unit, effective March 1.
  • Sales and Marketing for the Orthofix Bone Growth Therapies business.
  • View the full release here: https://www.businesswire.com/news/home/20240229167353/en/
    Orthofix names Jason Shallenberger as President, Bone Growth Therapies (Photo: Business Wire)
    Prior to this realignment, the Bone Growth Therapies business was managed under the leadership of the Company’s Spine business unit.
  • Bone Growth Therapies and Spine will now be led by separate Presidents in alignment with the Company’s current business structures for Biologics and Enabling Technologies.

Study Published in Nature Reveals Discovery of Unique Vertebral Stem Cells with Potential to Revolutionize Patient Care

Retrieved on: 
Thursday, September 21, 2023
Metastasis, Weill Cornell Medicine, Arm, Osteoporosis, Pathology, Cancer, Spine, Hope, Breast, Leg, Research, Prostate, Lung cancer, Cell, Doctor of Philosophy, Incidence, Hospital for Special Surgery, Thigh, MD, Patient, Physician, Organoid, Comprehension, HSS, Ossification, Hospital, B cell, Health, Bone fracture, Forearm, Dentistry, Nursing, Nature

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- In a groundbreaking study published in Nature, a collaborative team of researchers from Hospital for Special Surgery (HSS) and Weill Cornell Medicine have discovered a new stem cell uniquely present in the spine. Vertebral stem cells, distinct from other stem cells in the body, hold the key to understanding a range of conditions affecting the spine – including its higher incidence of cancerous tumor metastases, particularly from breast, prostate, and lung cancers. 

Key Points: 
  • Vertebral stem cells, distinct from other stem cells in the body, hold the key to understanding a range of conditions affecting the spine – including its higher incidence of cancerous tumor metastases, particularly from breast, prostate, and lung cancers.
  • For a long time, physicians believed all bones formed in the same way – through a universal process of ossification.
  • Specifically, the investigators identified a stem cell that is responsible for bone formation in the vertebrae.
  • However, our discovery of this vertebral stem cell provides a likely explanation of why some cancers most often spread to the spine," stated Dr. Greenblatt.

Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial

Retrieved on: 
Wednesday, May 17, 2023
Other Health, Stem Cells, Pharmaceutical, Surgery, Physical Therapy, Oncology, General Health, Medical Devices, Hospitals, Clinical Trials, Biotechnology, Science, Nursing, Research, Health, Medical Supplies, Infection, Spinal fusion, ASC, Bleeding, CPT, Amputation, Physiology, MicroRNA, Doctor of Philosophy, Teaching hospital, BNU, Patient, Extracellular matrix, GS, Ossification, Bone remodeling, Trauma, Safety, Injury, Dentistry, Medical imaging, EU, Tibia, MD

The patient was treated at the Saint-Luc University Hospital in Brussels by Dr. Pierre-Louis Docquier, EU principal investigator for this study.

Key Points: 
  • The patient was treated at the Saint-Luc University Hospital in Brussels by Dr. Pierre-Louis Docquier, EU principal investigator for this study.
  • Dr. Docquier has considerable clinical experience using ASC-based therapies generated from Novadip’s 3M3 tissue regeneration platform in clinical and compassionate use settings.
  • The Phase 1b/2a trial will enroll four CPT patients between two and eight years of age in the US and EU.
  • The primary endpoint of the study is short-term safety of NVD-003 up to 12 months following grafting surgery (GS).

UAT Group Subsidiary, Ossifix Orthopedics Begins Comparative Study

Retrieved on: 
Friday, January 20, 2023
Extremities, Holiday, Spine, Hospital, OTC Markets Group, Ossification, Comparison, Surgeon, Bone, Screw, Sandwich plate system, Allergy, Patient, Growth, Javelin, UAT, Elective surgery, Patent, UATG, Medical device, Dentistry

Tampa, FL, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc. (OTC Pink: UATG) (UAT Group) announce today that its subsidiary, Ossifix Orthopedics has begun a comparative study with doctors across six different sites.

Key Points: 
  • Tampa, FL, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc. (OTC Pink: UATG) (UAT Group) announce today that its subsidiary, Ossifix Orthopedics has begun a comparative study with doctors across six different sites.
  • The study will compare previously available traditional methods and materials versus The Ossifix Javelin allograft bone pin system.
  • Constructed of select, high-density, allograft, cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin ensures rigid fixation without pin slip or pirouetting.
  • I am encouraged with the progress they have made and look forward to the results of the comparative study”.

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

Retrieved on: 
Thursday, December 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Physical Therapy, Surgery, Health, Clinical Trials, Trauma, Injury, Ossification, CT, Human skeleton, IND, BNU, Doctor of Philosophy, DBM, MicroRNA, Patient, Tibia, Cancer, Extracellular matrix, How I Braved Anu Aunty and Co-Founded a Million Dollar Company, Mont-Saint-Guibert, Orthopedic surgery, Centre Hospitalier de Luxembourg, Ceramic, FDA, Pain, Diabetes, CPT, Obesity, Quality of life, US Foods, Physiology, Palpation, Smoking, Trial of the century, Safety, Nonunion, Centre hospitalier, Spinal fusion, OTE, Regeneration, Luxembourg, JAMA Surgery, Rush University Medical Center, Risk, Pharmaceutical industry, Medical imaging, Dentistry, Fracture, MD, EU

Highlights from the clinical study results include:

Key Points: 
  • Highlights from the clinical study results include:
    The results demonstrate NVD-003s ability to reverse severe bone deterioration and to achieve accelerated ossification.
  • A total of eight patients (89%) presented clinical healing during the two years of follow-up post-GS.
  • All patients achieved total weight bearing at six months and seven patients (78%) were walking normally at 2 years.
  • The studys primary endpoint was safety of NVD003 in adult patients with recalcitrant lower limb non-union.

Bone Growth Stimulators Market To Reach USD 1353.3 million by 2028 with a CAGR of 3.7% | Valuates Reports

Retrieved on: 
Friday, December 9, 2022
Hospital, BGS, Clinic, Accident, Device, PRP, Patient, Prevalence, Fracture, Medical device, FDA, Cros, Diabetes, Pain, Bone, Ossification, Obesity, Arthritis Foundation, Insurance, Vascular disease, COVID-19, Arthritis, Growth, Osteoarthritis, Bone marrow, Bone density, Bone Cancer Research Trust, Home, Transplant, BMP, USD, Dentistry, Antibiotics, Medical imaging

Due to the COVID-19 pandemic, the global Bone Growth Stimulators market size is estimated to be worth USD 1046.2 million in 2021 and is forecast to a readjusted size of USD 1353.3 million by 2028 with a CAGR of 3.7% during the forecast period 2022-2028.

Key Points: 
  • Due to the COVID-19 pandemic, the global Bone Growth Stimulators market size is estimated to be worth USD 1046.2 million in 2021 and is forecast to a readjusted size of USD 1353.3 million by 2028 with a CAGR of 3.7% during the forecast period 2022-2028.
  • The Bone Growth Stimulators market, however, is constrained by a number of variables, including the availability of alternative medicines, uncertainty about efficacy, device-related problems, and competition from bone grafts.
  • The increasing number of bone degeneration and accidents will drive the Bone Growth Stimulators market.
  • Bone Growth Stimulators Covered under medical insurance will drive Bone Growth Stimulators market growth.

Bone Growth Stimulator Market is expected to generate a revenue of USD 1.66 Billion by 2028, Globally, at 6.08% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, November 8, 2022
Trauma, BMP, Acquisition, Plasma, Diabetes, Oral, Instituto de Biologia Molecular e Celular, Sports medicine, Ossification, Platelet-rich plasma, Physician, PRP, Oral and maxillofacial surgery, Growth, Patient, Adoption, CAGR, Market research, DJO Global, Bone morphogenetic protein 2, Colfax Corporation, Cancer, Accident, Fracture, Geography, Obesity, Arthritis, Placenta, Bone, USD, Medtronic, Stryker Corporation, Elective surgery, Partnership, Johnson & Johnson, Prevalence, Cell, Research, Awareness, Surgeon, Spinal fusion, Dentistry

JERSEY CITY, N.J., Nov. 8, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Bone Growth Stimulator Market" By Product (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins, Platelet-Rich Plasma), By Application (Spinal Fusion Surgeries, Delayed Union & Nonunion Bone Fractures, Oral & Maxillofacial Surgeries), By Geographic Scope And Forecast.

Key Points: 
  • JERSEY CITY, N.J., Nov. 8, 2022 /PRNewswire/ --Verified Market Research recently published a report, " Bone Growth Stimulator Market " By Product (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins, Platelet-Rich Plasma), By Application (Spinal Fusion Surgeries, Delayed Union & Nonunion Bone Fractures, Oral & Maxillofacial Surgeries), By Geographic Scope And Forecast.
  • As per the deep research carried out by Verified Market Research, the global Bone Growth Stimulator Market size was valued at USD 1.04 Billion in 2020 and is projected to reach USD 1.66 Billion by 2028, growing at a CAGR of 6.08% from 2021 to 2028.
  • The Bone Growth Stimulator therapy is recommended by the physicians to help after a fracture or spinal fusion surgery to help the fractures repair more quickly.
  • Verified Market Research has segmented the Global Bone Growth Stimulator Market On the basis of Product, Application, and Geography.

Bone Growth Stimulator Market is expected to generate a revenue of USD 1.66 Billion by 2028, Globally, at 6.08% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, November 8, 2022
Trauma, BMP, Acquisition, Plasma, Diabetes, Oral, Instituto de Biologia Molecular e Celular, Sports medicine, Ossification, Platelet-rich plasma, Physician, PRP, Oral and maxillofacial surgery, Growth, Patient, Adoption, CAGR, Market research, DJO Global, Bone morphogenetic protein 2, Colfax Corporation, Cancer, Accident, Fracture, Geography, Obesity, Arthritis, Placenta, Bone, USD, Medtronic, Stryker Corporation, Elective surgery, Partnership, Johnson & Johnson, Prevalence, Cell, Research, Awareness, Surgeon, Spinal fusion, Dentistry

JERSEY CITY, N.J., Nov. 8, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Bone Growth Stimulator Market" By Product (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins, Platelet-Rich Plasma), By Application (Spinal Fusion Surgeries, Delayed Union & Nonunion Bone Fractures, Oral & Maxillofacial Surgeries), By Geographic Scope And Forecast.

Key Points: 
  • JERSEY CITY, N.J., Nov. 8, 2022 /PRNewswire/ --Verified Market Research recently published a report, " Bone Growth Stimulator Market " By Product (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins, Platelet-Rich Plasma), By Application (Spinal Fusion Surgeries, Delayed Union & Nonunion Bone Fractures, Oral & Maxillofacial Surgeries), By Geographic Scope And Forecast.
  • As per the deep research carried out by Verified Market Research, the global Bone Growth Stimulator Market size was valued at USD 1.04 Billion in 2020 and is projected to reach USD 1.66 Billion by 2028, growing at a CAGR of 6.08% from 2021 to 2028.
  • The Bone Growth Stimulator therapy is recommended by the physicians to help after a fracture or spinal fusion surgery to help the fractures repair more quickly.
  • Verified Market Research has segmented the Global Bone Growth Stimulator Market On the basis of Product, Application, and Geography.

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Retrieved on: 
Wednesday, August 31, 2022
European Medicines Agency, Mortality, PARK, Security (finance), COVID-19, EMA, Muscle, Ligament, FOP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Time, Disease, Genetic disorder, Society, HO, Deformity, RESEARCH, Food, BioCryst Pharmaceuticals, Galidesivir, U.S. Securities and Exchange Commission, PRIME, Marburg virus disease, Fast Track, Ossification, Patient, Joint, GLOBE, Movement, Nasdaq, FDA, Ligand, Yellow fever, Fibrodysplasia ossificans progressiva, Mutation, Annual report, Heterotopic ossification, Banca Monte dei Paschi di Siena, Tendon, Marketing, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).
  • We appreciate the FDAs decision to grant orphan drug designation to BCX9250 as we work toward our goal of bringing this important oral investigational therapy to FOP patients.
  • Earlier this year, BioCryst announced that BCX9250 has received Fast Track designation from the FDA, in addition to orphan drug designation and PRIME designation from the European Medicines Agency (EMA).
  • This press release contains forward-looking statements, including statements regarding BioCrysts plans and expectations for BCX9250 and the potential benefits associated with an FDA orphan drug designation.

FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

Retrieved on: 
Wednesday, June 8, 2022
Banca Monte dei Paschi di Siena, BioCryst Pharmaceuticals, Fast track (FDA), Time, Ligand, Heterotopic ossification, FOP, Marketing, PARK, Food, Tendon, Galidesivir, Annual report, PRIME, Security (finance), Disease, U.S. Securities and Exchange Commission, Nasdaq, Ligament, Yellow fever, FDA, GLOBE, Patient, Mortality, RESEARCH, Fast Track, Review, Fibrodysplasia ossificans progressiva, HO, COVID-19, Movement, Deformity, Marburg virus disease, Muscle, NDA, Ossification, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Joint, Mutation, Communication, Genetic disorder, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP).
  • According to the FDA, the purpose of the Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need.
  • We are pleased with the FDAs decision to grant Fast Track designation to BCX9250, as there is a significant unmet need among patients living with FOP.
  • This press release contains forward-looking statements, including statements regarding BioCrysts plans and expectations for BCX9250 and the potential benefits associated with an FDA Fast Track designation.